Clinical Trial Update: Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) [Phase 3]

View source ↗

Summary

This document provides an update on the NEPTUNE Phase 3 trial comparing durvalumab with tremelimumab versus standard-of-care as first-line therapy for metastati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (Imfinzi) (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: AstraZeneca | Conditions: Non Small Cell Lung Carcinoma NSCLC | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-05-24